Related Experiment Video
Updated: Jun 10, 2026
Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
Published on: January 28, 2020
Association Between Vascular Adhesion Protein-1 (VAP-1) and MACE in Patients with Coronary Heart Disease: A Cohort
You Zhang1, Chi Geng1, Yulun Zhou1
1Department of Cardiology, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province, People's Republic of China.
Insights
Higher serum Vascular Adhesion Protein-1 (VAP-1) levels indicate an increased risk of major adverse cardiovascular events (MACE) in coronary heart disease (CHD) patients. This finding highlights VAP-1 as a potential biomarker for cardiovascular risk stratification in CHD.
Area of Science:
- Cardiovascular Medicine
- Biomarkers
- Inflammation
Background:
- Vascular Adhesion Protein-1 (VAP-1) is an inflammation-inducible molecule implicated in cardiovascular diseases.
- The clinical significance of circulating VAP-1 levels in coronary heart disease (CHD) patients is not well-established.
Purpose of the Study:
- To investigate the association between serum VAP-1 levels and the risk of major adverse cardiovascular events (MACE) in patients with CHD.
- To explore the correlation between VAP-1 levels, coronary stenosis, and clinical manifestations in CHD patients.
Main Methods:
- Retrospective analysis of 336 hospitalized patients (174 with CHD).
- Serum VAP-1 measured by ELISA; MACE as primary endpoint.
- Statistical analyses included regression, curve fitting, and survival analysis.
Main Results:
- Higher serum VAP-1 levels were significantly associated with an increased risk of MACE in CHD patients after adjusting for confounders (HR = 5.11-5.81).
- No significant association was found between VAP-1 and MACE in the entire study population.
- VAP-1 levels did not correlate with coronary stenosis or clinical manifestations of CHD.
Conclusions:
- Elevated serum VAP-1 levels are a significant predictor of adverse cardiovascular outcomes in patients with CHD.
- VAP-1 may serve as a valuable biomarker for risk stratification in CHD.
- Further research is warranted to elucidate the precise role of VAP-1 in CHD pathogenesis.
Background:
Vascular adhesion protein-1 (VAP-1), an inflammation-inducible endothelial cell molecule, was reported to be implicated in a variety of cardiovascular diseases. However, the clinical significance of circulating VAP-1 levels in patients with coronary heart disease (CHD) remains less studied.
Patients And Methods:
We retrospectively analyzed clinical data of 336 hospitalized patients in the Second Affiliated Hospital of Soochow University from May 2020 to September 2022, 174 of which were diagnosed with CHD. Serum VAP-1 was measured by enzyme-linked immunosorbent assay at enrollment. The primary end point of this study was the occurrence of major adverse cardiovascular events (MACE). The coronary stenosis and clinical manifestations of CHD were assessed and recorded from medical records or follow-up calls. The relevant results were obtained, and the reliability of the conclusions was verified through regression analysis, curve fitting, and survival curve.
Results:
After adjusting for potential confounders, higher serum VAP-1 level was associated with increased risk of MACE in patients with CHD [(HR = 5.11, 95% CI = 1.02-25.59), (HR = 5.81, 95% CI = 1.16-29.11)]. The results of curve fitting and survival analysis were consistent with those of regression analysis. However, no significant association was observed between VAP-1 and MACE in the entire study population [(HR = 5.11, 95% CI = 0.41-1.93), (HR = 1.17, 95% CI = 0.52-2.62)]. Furthermore, the level of VAP-1 did not show a significant correlation with coronary stenosis and the clinical manifestations of CHD.
Conclusion:
These findings suggested that CHD patients with higher serum levels of VAP-1 are at a higher risk of adverse cardiovascular outcomes.
More Related Videos
07:25Predicting Amputation using Local Circulating Mononuclear Progenitor Cells in Angioplasty-treated Patients with Critical Limb Ischemia
Published on: September 22, 2020
08:51Author Spotlight: Integrated Multi-Omics Analysis for Unveiling Multicellular Immune Signatures in Clinical Heart Attack Cohorts
Published on: September 20, 2024
Related Concept Videos
01:30Coronary Artery Disease I: Introduction
01:26Coronary Artery Disease II: Pathophysiology
01:30Coronary Artery Disease III: Clinical Manifestations
01:26Coronary Artery Disease IV: Preventive Measures
01:30Acute Coronary Syndrome I: Introduction
01:30Acute Coronary Syndrome III: Diagnostic Studies